Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details

Education & Training

  • Fellowship Program, Pediatric Neuro-Oncology, 2010
    Duke University Medical Center
  • Fellowship Program, Pediatric Hematology/Oncology, 2008
    Duke University Medical Center
  • Residency Program, Pediatrics, 2005
    Hasbro Children's Hospital
  • Internship Program, Pediatrics, 2003
    Hasbro Children's Hospital
  • MD, 2002
    Duke University School of Medicine
  • BA, 1997
    Rice University

Board Certifications

  • American Board of Pediatrics/Hematology-Oncology

National Provider ID: 1356532592


Biography

Eugene (Gene) Hwang, M.D., is part of the Children's National Health System Pediatric Neuro-oncology team, focusing on treating children with brain tumors. Dr. Hwang has developed and led many novel early phase therapeutic clinical trials with a focus on immunotherapeutic trials, and he also leads trials focused on gene therapy and new, targeted agents. He is the site Principal Investigator of the Pediatric Brain Tumor Consortium, where he is the co-chair of the Immunotherapy Working Group. He serves on grant review committees and on the scientific advisory boards of several large foundations. For each patient, Dr. Hwang carefully considers the best possible options for treatment, trying new, cutting edge treatments coupled with the best available known therapies.

Dr. Hwang is not only dedicated to finding a cure for cancer, but also to making the current treatments as safe as possible for children. "We often focus on curing the children - that's the number one goal - but we also need to pay attention to the toxicity of these treatments, and what quality of life the children will have after treatment," he says. Dr. Hwang is involved in several international efforts to study how to best mitigate the side effects of treatment.

In the meantime, Dr. Hwang makes sure he's doing everything he can to combat pain, dizziness, fatigue and other common side effects of cancer treatments by leveraging the multidisciplinary team approach of Children's National. He sees this as something the organization does exceptionally well, and thinks that having so many people focus on a single patient in a single visit is crucial to well-being during cancer treatment.

Hwang E, Gururangan S, Herndon JE, Fuchs H, George T, Coleman RE. Fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. Neurosurgery. 2004;55(6):1280-1289. doi:10.1227/01.neu.0000143027.41632.2b.

Hwang EI, Jakacki RI, Fisher MJ, et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatric Blood & Cancer. 2012;60(5):776-782. doi:10.1002/pbc.24297.

Hwang EI, Emmenegger BA, et al. Distinct roles for fibroblast growth factor signaling in cerebellar development and medulloblastoma. Oncogene. 2012;32(35):4181-4188. doi:10.1038/onc.2012.440.

Hwang EI, Spence T, Sin-Chan P, et al. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathologica. 2014;128(2):291-303. doi:10.1007/s00401-014-1291-1.

Hwang EI, Bornhorst M. Experimental therapeutic trial design for pediatric brain tumors. Journal of Child Neurology. 2016;31(12):1421-1432. doi:10.1177/0883073815604221.

Hwang EI, Ramaswamy V, Hielscher T, et al. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis. Journal of Clinical Oncology. 2016;34(21):2468-2477. doi:10.1200/JCO.2015.65.7825.

Hwang EI, Nazarian J, Mason GE, et al. Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report. Oncotarget. 2016;7(27):42837-42842. doi:10.18632/oncotarget.10034.

Hwang EI, Pajtler KW, Mack SC, et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica. 2017;133(1):5-12. doi:10.1007/s00401-016-1643-0.